Candriam S.C.A. Keros Therapeutics, Inc. Call Options Transaction History
Candriam S.C.A.
- $17.1 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding KROS
# of Institutions
174Shares Held
30.3MCall Options Held
76.8KPut Options Held
9K-
Black Rock Inc. New York, NY2.51MShares$48.8 Million0.0% of portfolio
-
Alkeon Capital Management LLC New York, NY1.9MShares$36.9 Million0.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.86MShares$36.1 Million0.0% of portfolio
-
Darwin Global Management, Ltd. St. Helier, Y91.52MShares$29.6 Million7.2% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD1.51MShares$29.4 Million0.01% of portfolio
About Keros Therapeutics, Inc.
- Ticker KROS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,757,000
- Market Cap $500M
- Description
- Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...